ArticleBMC infectious diseases2025
Remdesivir safety and clinical outcomes in pediatric COVID-19: a retrospective study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluated clinical features of pediatric and adolescent patients with COVID-19 who received Remdesivir and assessed the adverse effects of Remdesivir in this population.
methodsIn a retrospective cross-sectional study, the documents of all patients under 18 years old were admitted due to severely respiratory distress and suspicious to COVID-19 in Taleghani hospital and according to Iranian COVID-19 treatment protocol received Remdesivir between February 2021 and September 2022, were studied.
resultsThe study included children aged 25 days to 17 years with a median age of 10 years and 50%being female. Fifteen patients were admitted to the ICU. 50% of ICU admissions were failure to thrive (FTT). BMI was significantly higher in patients over 10 years of age compared to others. Abnormal CT finding were observed in 90% of obese patients. Forty-one cases tested positive for PCR. The odds of PCR positivity were 2.87 times higher in patients over 10 years of age. Remdesivir was generally well tolerated, with no adverse events leading to drug discontinuation and no statistically significant difference in laboratory parameters before and after treatment. There were no significant hepatic or renal toxicity. Mild, transient elevations in liver transaminases (AST and ALT) were observed but did not require discontinuation of therapy. Transient bradycardia was not observed in our study.
conclusionRemdesivir appears to be a safe therapeutic option for pediatric COVID-19 patients, with minimal adverse effects and good tolerability. Nutritional status, particularly obesity and FTT, may influence disease severity. Further prospective studies are needed to better define Remdesivir’s role and its impact on viral clearance and clinical outcomes in children. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.